ASCO-contributor/ Oncology/ Partner content/ Partner Content/ Pharma Market Access/ Press releases

Ibrance approval cemented as competition comes into view

, , , , , 0 Comment

In February 2015,  Pfizer’s Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed